Hana Biosciences receives orphan drug designation for cancer drug Ropidoxuridine
13-Jun-2006
"This designation not only underscores the need for improved therapies in malignant glioma, it also reiterates the company's development strategy in areas of unmet need. Hana Biosciences is committed to the clinical development of Ropidoxuridine in this disease," commented Greg Berk, MD, Senior Vice President and Chief Medical Officer of Hana Biosciences.
Most read news
Topics
Organizations
FDA
Hana Biosciences
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.